New daily pill MP-214 tested for Long-Term schizophrenia control
NCT ID NCT01625897
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the long-term safety and effectiveness of a new daily pill called MP-214 in 125 people with chronic or elderly schizophrenia. Participants took either MP-214 or the existing drug risperidone for several weeks. The goal was to see if MP-214 is a safe and tolerable option for managing schizophrenia over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MP-214 (a once-daily pill) compared with risperidone (another antipsychotic pill)
What this could lead to
If successful, MP-214 could offer a new long-term treatment option for managing schizophrenia symptoms.
What could go wrong
This is an early-to-mid-stage study with only 125 participants, so results may not apply to everyone. Side effects are possible, and the drug may not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Aizu-Wakamatsu, Fukushima, Japan